Exabis Library
Welcome to the e-CCO Library!
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP51: De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP51: Loss of PTPN23 in the intestinal epithelium results in epithelial hyperproliferation and lethal diarrhea in a microbiota dependent manner
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP52 The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s disease or ulcerative colitis reflects the respective disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP52: Development of a host-microbe interaction workflow to reveal the cell- and condition-specific effects of a commensal bacteria upon IBD
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP52: Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP52: Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP52: The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn's disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP53 PTPN2 and TiO2 in the pathogenesis of inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP53: Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP53: Community types of the human gut virome are associated with endoscopic outcome in UC patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP53: In-depth characterisation of the serum antibody epitope repertoire in Inflammatory Bowel Disease by high-throughput phage-displayed immunoprecipitation sequencing
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP53: Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP54 Integrated network analysis using patient-specific single-nucleotide polymorphism profiles uncovers new pathways involved in ulcerative colitis pathogenesis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP54: Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP54: Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP54: Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn's disease – a systematic review and network meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM